1. Division of Bioequivalence II, Office of Generic Drugs, Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
2. Merck Sharp & Dohme Corp, Whitehouse Station, NJ, USA - The work was conducted while the author was with the FDA.